This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock PRTO vs. IKT, PLX, IZTC, CRTX, ZIVO, CVM, JATT, CLDI, FNCH, and ALVRShould you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), CEL-SCI (CVM), JATT Acquisition (JATT), Calidi Biotherapeutics (CLDI), Finch Therapeutics Group (FNCH), and AlloVir (ALVR). These companies are all part of the "medical" sector. Proteon Therapeutics vs. Its Competitors Inhibikase Therapeutics Protalix BioTherapeutics Invizyne Technologies Cortexyme ZIVO Bioscience CEL-SCI JATT Acquisition Calidi Biotherapeutics Finch Therapeutics Group AlloVir Inhibikase Therapeutics (NYSE:IKT) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk. Which has stronger earnings and valuation, IKT or PRTO? Proteon Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.57Proteon TherapeuticsN/AN/A-$20.73M-$1.15-2.66 Is IKT or PRTO more profitable? Proteon Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% Proteon Therapeutics N/A N/A -118.68% Do analysts recommend IKT or PRTO? Inhibikase Therapeutics presently has a consensus target price of $6.50, indicating a potential upside of 327.63%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Inhibikase Therapeutics is more favorable than Proteon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Proteon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, IKT or PRTO? Inhibikase Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Does the media refer more to IKT or PRTO? In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Proteon Therapeutics. MarketBeat recorded 1 mentions for Inhibikase Therapeutics and 0 mentions for Proteon Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.67 beat Proteon Therapeutics' score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Inhibikase Therapeutics Positive Proteon Therapeutics Neutral Do insiders & institutionals have more ownership in IKT or PRTO? 3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryInhibikase Therapeutics beats Proteon Therapeutics on 8 of the 13 factors compared between the two stocks. Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTO vs. The Competition Export to ExcelMetricProteon TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.87M$267.85M$5.48B$9.51BDividend YieldN/AN/A4.73%4.09%P/E Ratio-2.66N/A28.6723.80Price / SalesN/A327.48373.9066.58Price / CashN/A22.4435.4557.96Price / Book-51.0010.418.275.55Net Income-$20.73M-$106.40M$3.24B$259.03M Proteon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTOProteon TherapeuticsN/A$3.06-1.3%N/A+39.0%$67.87MN/A-2.6617IKTInhibikase Therapeutics2.0854 of 5 stars$1.70-4.0%$6.50+282.4%+10.9%$126.38MN/A-0.646News CoveragePLXProtalix BioTherapeutics2.2289 of 5 stars$1.46-2.7%$15.00+927.4%+36.2%$116.23M$59.76M-11.23200News CoverageGap DownIZTCInvizyne TechnologiesN/A$9.98+0.3%N/AN/A$62.40MN/A0.0029Positive NewsGap UpCRTXCortexymeN/A$1.85-0.5%N/A+127.2%$55.78MN/A-0.6255News CoverageZIVOZIVO BioscienceN/A$10.70-3.2%N/A+18.7%$40.84M$15.85K-2.1910CVMCEL-SCI1.2111 of 5 stars$7.15-17.0%N/A-72.6%$38.05MN/A-14.9043Positive NewsShort Interest ↑High Trading VolumeJATTJATT AcquisitionN/A$1.64-2.4%N/A-62.8%$28.29MN/A0.003High Trading VolumeCLDICalidi Biotherapeutics0.2029 of 5 stars$0.63+14.9%N/A-64.7%$22.94MN/A0.0038Short Interest ↑Gap DownHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$12.50-0.4%N/A+556.3%$20.08MN/A-1.42190ALVRAlloVirN/A$2.93+6.0%N/A-85.4%$14.75MN/A-0.14110Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies Inhibikase Therapeutics Alternatives Protalix BioTherapeutics Alternatives Invizyne Technologies Alternatives Cortexyme Alternatives ZIVO Bioscience Alternatives CEL-SCI Alternatives JATT Acquisition Alternatives Calidi Biotherapeutics Alternatives Finch Therapeutics Group Alternatives AlloVir Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRTO Stock Alerts